Patisiran Infusion Suppliers & Bulk Manufacturers
Available Forms: Intravenous (IV) infusion
Available Strengths: 0.3 mg/mL
Reference Brands: Onpattro
Category:
Nanoemulsion/Nanoparticles
Patisiran (Onpattro) inhibits transthyretin (TTR) production in the liver via RNA interference, reducing misfolded TTR protein accumulation. Benefits include slowing disease progression, alleviating neurological and cardiac symptoms, and improving quality of life in hereditary transthyretin amyloidosis patients when administered properly in specialized centers.
Product Description:
Patisiran (Onpattro) is regulated in both the EU and US, supported by dossiers demonstrating safety, efficacy, and manufacturing quality in compliance with GMP standards. In the US, FDA approval involved rigorous clinical validation, safety assessments, and pharmacovigilance. In the EU, CE marking certifies conformity under MDR standards. These biologics undergo validation, stability testing, and audits, with comprehensive documentation including safety profiles, clinical trial data, and manufacturing practices. For licensing procedures, approved dossiers, and the latest regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to effective, life-saving therapies supporting patients with hereditary ATTR amyloidosis worldwide, promoting safe and optimal patient outcomes.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing